EP0643724A1 - Process of preparing 3-carbonylandrostadiene 17-carboxamides - Google Patents

Process of preparing 3-carbonylandrostadiene 17-carboxamides

Info

Publication number
EP0643724A1
EP0643724A1 EP93904946A EP93904946A EP0643724A1 EP 0643724 A1 EP0643724 A1 EP 0643724A1 EP 93904946 A EP93904946 A EP 93904946A EP 93904946 A EP93904946 A EP 93904946A EP 0643724 A1 EP0643724 A1 EP 0643724A1
Authority
EP
European Patent Office
Prior art keywords
compound
process according
formula
moieties
cyanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93904946A
Other languages
German (de)
French (fr)
Other versions
EP0643724A4 (en
Inventor
Neil Howard Baine
Franklin Fell Owings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0643724A1 publication Critical patent/EP0643724A1/en
Publication of EP0643724A4 publication Critical patent/EP0643724A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Definitions

  • the present invention relates to an improved process for the conversion of substituted steroidal 3- halogen 3 , 5 diene derivatives to substituted steroidal 3 , 5-diene-3-carboxylic acid derivatives .
  • Such compounds are described in U . S . Patent No . 5 , 017 , 568 , issued on May 21 , 1991 to Holt , et al . as being useful in inhibiting steroid 5- ⁇ -reductase .
  • N-butyl lithium and ethylmagnesium bromide and ethylmagnesium chloride are expensive reagents adding significant cost to an industrial process. Further, N-butyl lithium is flammable and the carboxylation reaction is performed at dilute concentrations, Thus, there is a need in the art for a safe, economical and reliable method to convert substituted steroidal 3-halogen 3,5 diene derivatives to substituted steroidal 3,5-diene-3-carboxylic acid derivatives.
  • This invention relates to an improved process for converting steroidal 3-halogen 3,5 diene derivatives to steroidal 3,5-diene-3-carboxylic acid derivatives.
  • This invention specifically relates to an improved process for the preparation of N-t-butyl-androst-3,5- diene-17 ⁇ -carboxamide-3-carboxylic acid.
  • halogen as used herein and in the claims means chlorine, bromine or iodine.
  • halogen as used herein means bromine or iodine.
  • the present invention provides a process for the production of a compound of Formula (I)
  • R 2 and R ⁇ are each independently selected from hydrogen, C3_gcycloalkyl and phenyl; or R 2 and R3 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
  • X is halogen; in the presence of a cyanating reagent and an appropriate solvent, preferably dimethylformamide, to form a compound of Formula (III)
  • R 1 is as defined above and subsequently saponifying the compound of Formula (III) to form a compound of Formula (I) and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • R 1 is; (i) CONR 2 R 3 , where R 2 and R 3 are each independently selected from hydrogen, C]__galkyl, C3_gcycloalkyl and phenyl; or
  • R ⁇ is ⁇ -CONR R 3 , where R 2 and R 3 are each independently selected from hydrogen, C ⁇ -galkyl, C3_gcycloalkyl and phenyl.
  • Compounds of Formula I comprise R ⁇ - or moieties which can be chemically converted to those of R 1 by known chemical reactions such as described in Arthur Barton and U.D. Ollis, Comprehensive Organic Chemistry:
  • R 1 does not include any such moieties that render inoperative the presently invented process.
  • Reactions to convert said moieties to R 1 are performed on products of the synthetic pathways disclosed or claimed herein or, where appropriate or preferable on certain intermediates in these synthetic pathways.
  • carboxylic acid substituents can be converted to the carboxamide by conversion to the acid halide followed by reacting the same with an amine.
  • Esters can be converted to the acid and treated as above.
  • Nitriles can be converted to carboxamides by reaction with an alkylating agent, such as t- butylacetate or t-butanol, under acidic catalysis.
  • R 1 is (i) CONR 2 R 3 , where R 2 and R 3 are each independently selected from hydrogen, C ⁇ _8alkyl, C3_gcycloalkyl and phenyl; or R 2 and R 3 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
  • R 1 is; (i) CONR 2 R 3 , where R 2 and R 3 are each independently selected from hydrogen, Ci- ⁇ alkyl, C3_gcycloalkyl and phenyl; or
  • R-1- is; ⁇ -CONR 2 R 3 , where R 2 and R 3 are each independently selected from hydrogen, C ⁇ _8alkyl, C3_gcycloalkyl and phenyl.
  • reagents and conditions used to convert 3-halogen steroidal-3,5-dienes to steroidal-3,5-diene 3-carboxylic acids are safe, inexpensive, can be reacted in high concentrations and result in high yields of the desired compound thereby rendering said processes appropriate for industrial scale utilization.
  • Chalky means a straight or branched hydrocarbon chain having C ⁇ _ n carbons.
  • cyanating reagent as used herein and in the claims is meant reagents which are capable of reacting, under certain conditions, with a halogenated moiety to form a cyanated moiety.
  • a cyanating reagent is prepared by reacting the corresponding halogenated moiety with a cyanating reagent in an appropriate solvent, such as N,N-dimethyl- N,N-propylene urea (DMPU) , N,N-dimethylformamide (DMF) or N-methyl-2-pyrrolidinone (NMP) , preferably DMF, at increased temperatures.
  • an appropriate solvent such as N,N-dimethyl- N,N-propylene urea (DMPU) , N,N-dimethylformamide (DMF) or N-methyl-2-pyrrolidinone (NMP) , preferably DMF
  • saponifying as used herein and in the claims is meant a compound or reagent or a series of reagents which are capable of reacting with a nitrile to form a carboxylic acid substituted moiety under appropriate conditions.
  • carboxylic acid substituted moiety is prepared by reacting the corresponding cyanated moiety with a hydroxide base, preferably aqueous sodium hydroxide, in an appropriate solvent, such as; ethylene glycol, isopropyl alcohol or ethanol, preferably ethanol, at increased temperatures with subsequent acidification.
  • cyanating reagents for use in the presently invented process utilize cyanide complexes such as described in Richard C. Larock, Comphrehensive Organic Transforma ons: ft Guide tQ Functional GrOUP Prepara ons. Pub: VCH Publishers, Inc. (1989) P. 861.
  • An example of a cyanide complex as used herein is the in situ co-mixture of KCN, iBr2 (PP ⁇ 13)2, Zn, PPh.3.
  • NaCu(CN)2 refers to the reagent formed by co- mixing CuCN and NaCN in situ.
  • Preferred among the above cyanating complexes are CuCN and NaCu(CN) 2 .
  • Preferably said NaCu(CN)2 complex is prepared by adding 1 molar equivalent of sodium cyanide to cuprous cyanide in situ.
  • solvent or "appropriate solvent” as used herein and in the claims is meant a solvent such as methylene chloride, ethylene chloride, chloroform, ethylene glycol, carbon tetrachloride, tetrahydrofuran (THF) , ethyl ether, toluene, ethyl acetate, dimethylsulfoxide, N,N l -dimethyl-N,N'-propylene urea, N- methyl-2-pyrrolidinone, methanol, isopropylalcohol, dimethylformamide, water, pyridine, quinoline or ethanol.
  • the process of the present invention is particularly useful for preparing a compound of structure (IIIA)
  • Androst-4-en-3-one-17 ⁇ -carboxylic acid 10.0 grams (1 molar equivalent) was added to the resulting white suspension and the mixture was warmed to room temperature and stirred for 2 hours.
  • the reaction mixture was quenched into a vessel containing 100 mL of methylene chloride and 23.1 grams (10 molar equivalents) of tert-butylamine while maintaining the temperature between 0-10°C.
  • the mixture was stirred for 30 minutes. About 100 mL of water were added and the biphase mixture was filtered through a pad of Celite. The organic phase was separated and reduced to about half its volume by vacuum distillation. The solution was restored to its original volume with acetone. This concentration/fill procedure was repeated twice more.
  • the organic phase was washed with three 200 mL portions of 50/50 v/v cone. aqueous ammonia/water, followed by two 200 L portions of water.
  • the organic phase was concentrated under vacuum to 150 mL and 250 mL of ethanol were added.
  • the solution was again concentrated under vacuum to 150 mL, and 250 L of ethanol were added.
  • the solution was concentrated under vacuum to 300 mL, and 30 mL of water were added to induce crystallization.
  • the resulting suspension was chilled for 2 hours at 0-5°C.
  • N-t-butvl-androst-3.5-diene-3-cvano-17 ⁇ -carboxamide A 5 L 3-neck flask (Morton) equipped with a mechanical stirrer, thermometer, and reflux condenser was charged with 250 grams of N-t-butyl-androst-3,5- diene-3-bromo-17 ⁇ -carboxamide (prepared as in Example 1 (i) ) , 55 grams of cuprous cyanide, 29 grams of sodium cyanide, and 1 liter of dimethylformamide. The reaction mixture was heated to reflux (152-153°C) for at least 12 hours.
  • the reaction mixture was slowly cooled to 25- 30°C with a cold water bath, and was quenched with one liter of 50% aqueous ammonium hydroxide (50/50 v/v cone, ammonia/water) with rapid stirring. After stirring 15- 20 minutes, one liter of methylene chloride was charged, and the two phase system was allowed to separate. The phases were separated and the aqueous phase was reextracted with 2 x 500 mL of methylene chloride. The combined methylene chloride extracts were passed through a celite filter pad to remove insoluble copper salts. The celite pad was washed with 150 mL of methylene chloride.
  • the combined methylene chloride phases were washed with 3 x 500 mL ammonium hydroxide to remove last traces of copper salts.
  • the organic phase was concentrated by atmospheric distillation, removing approximately 1.5 liters of methylene chloride.
  • a 600 mL portion of ethanol was charged to the reactor and the concentration/displacement of methylene chloride was continued by distilling a second 500 mL portion of solvent.
  • a second 600 mL portion of ethanol was charged to the reactor and the atmospheric distillation was continued until the vapor temperature reached 82-84°C.
  • a 60 mL portion of water was charged to the reactor and the resulting suspension was chilled at 0-5°C for at least two hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invented is an improved process for the preparation of substituted steroidal dienes. Also invented are novel intermediates used in said process.

Description

Process of Preparing 3-Carbonylandrostadiene 17-Carboxamides
The present invention relates to an improved process for the conversion of substituted steroidal 3- halogen 3 , 5 diene derivatives to substituted steroidal 3 , 5-diene-3-carboxylic acid derivatives . Such compounds are described in U . S . Patent No . 5 , 017 , 568 , issued on May 21 , 1991 to Holt , et al . as being useful in inhibiting steroid 5-α-reductase .
Ban rnnnd of the Invention
Processes for the preparation of substituted steroidal 3,5-diene-3-carboxylic acid derivatives from substituted steroidal 3-halogen 3,5 diene intermediates have previously been described. In particular the use of catalytic or alkyllithium mediated carboxylation of steroidal 3-bromo-3,5 diene intermediates to yield steroidal-3,5-diene-3-carboxylic acid derivatives (in 15% yield when N-butyl lithium was used) is reported in U.S. Patent No. 5,017,568. The use of a basic medium, when applicable, to selectively deprotonate acidic hydrogen atoms of the brominated intermediate in the above reaction prior to the addition of a dehalogenating reagent has been shown to increase the yield of the resulting steroidal 3,5 diene-3-carboxylic acid derivative in U.S. Application No. 07/817,179 filed on January 6, 1992 (63% for the preparation of N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid from N-t-butyl-androst-3,5-diene-3-bromo-17β-carboxamide) . Disclosed therein as preferred bases utilized in preparing said basic medium are ethylmagnesium bromide and ethylmagnesium chloride.
In addition to a low overall yield, the principle shortcoming of these disclosures is that N-butyl lithium and ethylmagnesium bromide and ethylmagnesium chloride are expensive reagents adding significant cost to an industrial process. Further, N-butyl lithium is flammable and the carboxylation reaction is performed at dilute concentrations, Thus, there is a need in the art for a safe, economical and reliable method to convert substituted steroidal 3-halogen 3,5 diene derivatives to substituted steroidal 3,5-diene-3-carboxylic acid derivatives.
Summary of h Invention This invention relates to an improved process for converting steroidal 3-halogen 3,5 diene derivatives to steroidal 3,5-diene-3-carboxylic acid derivatives.
This invention specifically relates to an improved process for the preparation of N-t-butyl-androst-3,5- diene-17β-carboxamide-3-carboxylic acid.
In a further aspect of the invention there are provided novel intermediates useful in the presently invented process.
As used above and throughout the remainder of the specification and claims the carbons of the steroid nucleus are numbered and the rings are lettered as follows:
Pharmaceutically acceptable salts hydrates and solvates of Formula (I) compounds are formed where appropriate by methods well known to those of skill in the art. Unless otherwise specified the term "halogen" as used herein and in the claims means chlorine, bromine or iodine.
Preferably the term "halogen" as used herein means bromine or iodine. The present invention provides a process for the production of a compound of Formula (I)
in which
R1 is
(i) CONR2R3, where R2 and R^ are each independently selected from hydrogen, C3_gcycloalkyl and phenyl; or R2 and R3 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
(ii) moieties which are chemically convertible to moieties of (i) , such as -C=N, -COOH or -COOCi-galkyl; or a pharmaceutically acceptable salt, hydrate or solvate thereof, which comprises cyanation of a compound of Formula (II)
in which R1 is as defined above and
X is halogen; in the presence of a cyanating reagent and an appropriate solvent, preferably dimethylformamide, to form a compound of Formula (III)
in which R1 is as defined above and subsequently saponifying the compound of Formula (III) to form a compound of Formula (I) and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate thereof.
Preferably R1, as used in the above process, is; (i) CONR2R3, where R2 and R3 are each independently selected from hydrogen, C]__galkyl, C3_gcycloalkyl and phenyl; or
(ii) -CΞN,-COOH or -COOCx-galkyl.
Most, preferably R^, as used in the above process, is β-CONR R3, where R2 and R3 are each independently selected from hydrogen, C^-galkyl, C3_gcycloalkyl and phenyl.
Compounds of Formula I comprise R^- or moieties which can be chemically converted to those of R1 by known chemical reactions such as described in Derek Barton and U.D. Ollis, Comprehensive Organic Chemistry:
The Synthesis and Reactions of Qrgainc Compounds. Pub: Pergamon Press (1979) provided that R1 does not include any such moieties that render inoperative the presently invented process. Reactions to convert said moieties to R1 are performed on products of the synthetic pathways disclosed or claimed herein or, where appropriate or preferable on certain intermediates in these synthetic pathways. For example, carboxylic acid substituents can be converted to the carboxamide by conversion to the acid halide followed by reacting the same with an amine. Esters can be converted to the acid and treated as above. Nitriles can be converted to carboxamides by reaction with an alkylating agent, such as t- butylacetate or t-butanol, under acidic catalysis.
In utilizing the presently invented process to prepare compounds of Formula (I) , novel intermediates of the following Formula (IV) are synthesized;
in which: R1 is (i) CONR2R3, where R2 and R3 are each independently selected from hydrogen, Cι_8alkyl, C3_gcycloalkyl and phenyl; or R2 and R3 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
(ii) moieties which are chemically convertible to moieties of (i) , such as -C= N, -COOH or -COOCi-galkyl;
Preferably R1, as used in the above compound of formula (iv) , is; (i) CONR2R3, where R2 and R3 are each independently selected from hydrogen, Ci-βalkyl, C3_gcycloalkyl and phenyl; or
(ii) -C=N,-COOH or -COOCι_gal yl.
Most preferably R-1-, as used in the above compound of formula (IV) , is; β-CONR2R3, where R2 and R3 are each independently selected from hydrogen, Cι_8alkyl, C3_gcycloalkyl and phenyl.
The presently invented process discloses several advantages over the cited references. Specifically, reagents and conditions used to convert 3-halogen steroidal-3,5-dienes to steroidal-3,5-diene 3-carboxylic acids are safe, inexpensive, can be reacted in high concentrations and result in high yields of the desired compound thereby rendering said processes appropriate for industrial scale utilization.
As used herein and in the claims, unless otherwise specified, Chalky! means a straight or branched hydrocarbon chain having Cι_n carbons.
By the term "cyanating reagent" as used herein and in the claims is meant reagents which are capable of reacting, under certain conditions, with a halogenated moiety to form a cyanated moiety. Preferably said cyanated moiety is prepared by reacting the corresponding halogenated moiety with a cyanating reagent in an appropriate solvent, such as N,N-dimethyl- N,N-propylene urea (DMPU) , N,N-dimethylformamide (DMF) or N-methyl-2-pyrrolidinone (NMP) , preferably DMF, at increased temperatures.
By the term "saponifying" as used herein and in the claims is meant a compound or reagent or a series of reagents which are capable of reacting with a nitrile to form a carboxylic acid substituted moiety under appropriate conditions. Preferably said carboxylic acid substituted moiety is prepared by reacting the corresponding cyanated moiety with a hydroxide base, preferably aqueous sodium hydroxide, in an appropriate solvent, such as; ethylene glycol, isopropyl alcohol or ethanol, preferably ethanol, at increased temperatures with subsequent acidification.
By the term "increased temperatures" as used herein and in the claims is meant above 25°C, preferably at reflux temperatures. Preferably cyanating reagents for use in the presently invented process utilize cyanide complexes such as described in Richard C. Larock, Comphrehensive Organic Transforma ons: ft Guide tQ Functional GrOUP Prepara ons. Pub: VCH Publishers, Inc. (1989) P. 861. An example of a cyanide complex as used herein is the in situ co-mixture of KCN, iBr2 (PPΪ13)2, Zn, PPh.3. Other
3- examples include: Co(CN) 4; K4N12 (CH) , KCN; KCN, cat 3-
Pd(PPh3>4; Co(CN) 5; CuCN and NaCu(CN)2- As used herein the term "NaCu(CN)2" refers to the reagent formed by co- mixing CuCN and NaCN in situ.
Preferred among the above cyanating complexes are CuCN and NaCu(CN)2.
Particularly preferred among the above cyanating complexes is NaCu(CN)2•
Preferably said NaCu(CN)2 complex is prepared by adding 1 molar equivalent of sodium cyanide to cuprous cyanide in situ.
By the term "solvent" or "appropriate solvent" as used herein and in the claims is meant a solvent such as methylene chloride, ethylene chloride, chloroform, ethylene glycol, carbon tetrachloride, tetrahydrofuran (THF) , ethyl ether, toluene, ethyl acetate, dimethylsulfoxide, N,Nl-dimethyl-N,N'-propylene urea, N- methyl-2-pyrrolidinone, methanol, isopropylalcohol, dimethylformamide, water, pyridine, quinoline or ethanol. Preferably, therefore, the process of the present invention is particularly useful for preparing a compound of structure (IIIA)
and converting the same into the following compound of structure (IA)
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
EXAMPLES Dimethylformamide, and cuprous cyanide are available from Aldrich Chemical Co, (Milwaukee, WI) androst-4-en-3-one-17β-carboxylic acid is available from Berlichem, Inc. (Wayne, NJ) .
Example 1
N-t-frutyl-androst-3,5-dieneτl7fircarboxamide-3-
(i) N-t-butyl-androst-3,5-diene-3-bromo-17β- carboxamide
A flask under nitrogen atmosphere was charged with 100 L of methylene chloride and 6.12 mL (2.5 molar equivalents) of dimethylformamide. The solution was cooled to 0-5°C, and was treated with 6.9 mL (2.5 molar equivalents) of oxalyl chloride while maintaining the temperature between 0-10°C. A white precipitate formed. After stirring for one hour, 50.1 grams (19.6 molar equivalents) of hydrogen bromide gas were bubbled through the solution while maintaining the temperature between 0-10°C. The suspension became a clear colorless solution. The solution was degassed by reducing the solution volume by about one-half by vacuum distillation and restoring to its original volume with methylene chloride. This concentration/refill procedure was repeated. Androst-4-en-3-one-17β-carboxylic acid, 10.0 grams (1 molar equivalent) , was added to the resulting white suspension and the mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was quenched into a vessel containing 100 mL of methylene chloride and 23.1 grams (10 molar equivalents) of tert-butylamine while maintaining the temperature between 0-10°C. The mixture was stirred for 30 minutes. About 100 mL of water were added and the biphase mixture was filtered through a pad of Celite. The organic phase was separated and reduced to about half its volume by vacuum distillation. The solution was restored to its original volume with acetone. This concentration/fill procedure was repeated twice more. The resulting acetone solution (about 300 mL) was warmed to about 50°C and was treated with about 100 mL of water to precipitate the product. The suspension was cooled, and the product, N- t-butyl-androst-3,5-diene-3-bromo-17β-carboxamide, was isolated by filtration and dried. Yield 89%, mp 181- 183°C.
(ii) N-t-butvl-androst- .5-diene-3-cyano-l7β- carboxamide
A stirred mixture of N-t-butyl-androst-3,5-diene-3- bromo-17β-carboxamide (50 grams, 1 molar equivalent) , cuprous cyanide (11.0 grams, 1.1 molar equivalents), and dimethylformamide (200 mL) was heated to reflux for 3.5 hours. The reaction was cooled to 90-100°C and quenched with stirring into a solution of 100 mL of cone, aqueous ammonia and 200 mL of water. The reaction flask was rinsed out with 25 mL of dimethylformamide, which was also added to the quench solution. The resulting suspension was extracted twice with 200 mL portions of methylene chloride, and the organic extracts were filtered through a pad of celite. The organic phase was washed with three 200 mL portions of 50/50 v/v cone. aqueous ammonia/water, followed by two 200 L portions of water. The organic phase was concentrated under vacuum to 150 mL and 250 mL of ethanol were added. The solution was again concentrated under vacuum to 150 mL, and 250 L of ethanol were added. The solution was concentrated under vacuum to 300 mL, and 30 mL of water were added to induce crystallization. The resulting suspension was chilled for 2 hours at 0-5°C. The solid product was collected by filtration and was dried at 65°C under vacuum to afford 37.0 grams of N-t-butyl- androst-3,5-diene-3-cyano-17β-carboxamide as yellow crystals in 85% yield, mp 195-197°C.
(iii) N-t-butyl-androπt-3, -diene-17β-carfrQxamide-
A mixture of N-t-butyl-androst-3,5-diene-3-cyano- 17β-carboxamide (20.0 grams, 1 molar equivalent), 50% aqueous sodium hydroxide (80 mL, 30 molar equivalents) , and ethanol (200 mL) was heated to reflux for 18 hours. The reaction suspension was cooled to 50°C and was added to a stirred mixture of 6N hydrochloric acid (300 mL) and methylene chloride (200 mL) . The final pH of the aqueous phase was 1.5-2.0. The organic phase was separated and the aqueous phase was reextracted with 250 mL of methylene chloride. The combined organic phases were stirred with 2 grams of decolorizing charcoal for one hour and were filtered through a pad of celite. The organic phase was concentrated under vacuum to 120 mL and 200 mL of ethyl acetate were added. The suspension was again concentrated under vacuum to 120 mL and 200 mL of ethyl acetate were added. The resulting suspension was concentrated under vacuum to a final volume of 120 mL and was heated at reflux for 2 hours. The suspension was chilled at 0-5°C for two hours and filtered. The solid product was dried under vacuum at 65°C to afford 14.8 grams, 71% yield, of N-t-butyl-androst-3,5-diene- 17β-carboxamide-3-carboxylic acid. Recrystalization of the mother liquors afforded an additional 3.14 grams (15% yield) of product. 86% total yield for reaction. mp 250-251°C. Example 2
N-t-butvl-androst-3.5-diene-3-cvano-17β-carboxamide A 5 L 3-neck flask (Morton) equipped with a mechanical stirrer, thermometer, and reflux condenser was charged with 250 grams of N-t-butyl-androst-3,5- diene-3-bromo-17β-carboxamide (prepared as in Example 1 (i) ) , 55 grams of cuprous cyanide, 29 grams of sodium cyanide, and 1 liter of dimethylformamide. The reaction mixture was heated to reflux (152-153°C) for at least 12 hours. The reaction mixture was slowly cooled to 25- 30°C with a cold water bath, and was quenched with one liter of 50% aqueous ammonium hydroxide (50/50 v/v cone, ammonia/water) with rapid stirring. After stirring 15- 20 minutes, one liter of methylene chloride was charged, and the two phase system was allowed to separate. The phases were separated and the aqueous phase was reextracted with 2 x 500 mL of methylene chloride. The combined methylene chloride extracts were passed through a celite filter pad to remove insoluble copper salts. The celite pad was washed with 150 mL of methylene chloride. The combined methylene chloride phases were washed with 3 x 500 mL ammonium hydroxide to remove last traces of copper salts. The organic phase was concentrated by atmospheric distillation, removing approximately 1.5 liters of methylene chloride. A 600 mL portion of ethanol was charged to the reactor and the concentration/displacement of methylene chloride was continued by distilling a second 500 mL portion of solvent. A second 600 mL portion of ethanol was charged to the reactor and the atmospheric distillation was continued until the vapor temperature reached 82-84°C. A 60 mL portion of water was charged to the reactor and the resulting suspension was chilled at 0-5°C for at least two hours. The solid was collected, washed with 75 mL 50% aqueous alcohol and dried at 60-65°C under vacuum to yield 191.3 grams of the title compound. 88% yield; mp=190-192°C.
While the preferred embodiments of the invention are illustrated by the above, it is understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

What is claimed is:
1. A process for the preparation of a compound of Formula (I)
in which and R1 is
(i) CONR3R4, where R3 and R4 are each independently selected from hydrogen, Cι_8alkyl, C3_ gcycloalkyl, phenyl; or R3 and R4 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
(ii) moieties which are chemically convertible to moieties of (i) ; or a pharmaceutically acceptable salt, hydrate or solvate thereof, which comprises cyanation of a compound of Formula (II)
in which R^ is as defined above and X is halogen, in the presence of a cyanating reagent and an appropriate solvent to form a compound of Formula (III)
in which R^ is as defined above and subsequently saponifying the compound of Formula (III) to form a compound of Formula (I) and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate.
2. A process according to claim 1 in which the cyanating reagent comprises a cyanide complex of the formula CuCN and NaCu(CN)2-
3. A process according to claim 2 in which the cyanating reagent consists of a cyanide complex of the formula NaCu(CN) 2.
4. A process according to claim 3 in which the cyanide complex of the formula NaC (CN) 2 is prepared by adding 1 molar equivalent of sodium cyanide to cuprous cyanide in situ..
5. A process according to claim 2 in which the cyanide complex is cuprous cyanide.
6. A process according to claim 1 in which X is bromine.
7. A process according to claim 1 in which said solvent is dimethylformamide.
8. The process according to claim 1 in which the saponification comprises reacting N-t-butyl-androst-3,5- diene-3-cyano-17β-carboxamide and a hydroxide base in an appropriate solvent with subsequent acidification.
9. The process according to claim 8 in which the appropriate solvent is ethanol.
10. The process according to claim 9 in which the base is aqueous sodium hydroxide.
11. A process according to claim 1 in which the compound prepared is
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
12. A compound of the structure
in which
R1 is
(i) CONR2R3, where R2 and R3 are each independently selected from hydrogen, C3_gcycloalkyl, phenyl; or R2 and R3 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or
(ii) moieties which are chemically convertible to moieties of (i) .
13. A compound of claim 12 wherein R^ is -C≤N, -COOH, -COOCi-galkyl or -CON(H) t-butyl.
14. A compound of claim 13 wherein R1 is -CON(H)t- butyl.
15. A compound of claim 13 wherein R1 is -COOH.
16. A compound of claim 13 wherein R1 is -C=N.
EP93904946A 1992-02-07 1993-02-05 Process of preparing 3-carbonylandrostadiene 17-carboxamides. Ceased EP0643724A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US832280 1986-02-24
US83228092A 1992-02-07 1992-02-07
PCT/US1993/001068 WO1993016097A1 (en) 1992-02-07 1993-02-05 Process of preparing 3-carbonylandrostadiene 17-carboxamides

Publications (2)

Publication Number Publication Date
EP0643724A1 true EP0643724A1 (en) 1995-03-22
EP0643724A4 EP0643724A4 (en) 1995-05-10

Family

ID=25261209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93904946A Ceased EP0643724A4 (en) 1992-02-07 1993-02-05 Process of preparing 3-carbonylandrostadiene 17-carboxamides.

Country Status (23)

Country Link
EP (1) EP0643724A4 (en)
JP (1) JPH07505140A (en)
KR (1) KR950700319A (en)
CN (1) CN1078475A (en)
AP (1) AP9600790A0 (en)
AU (1) AU666177B2 (en)
BG (1) BG98955A (en)
BR (1) BR9305837A (en)
CA (1) CA2129342A1 (en)
CZ (1) CZ188794A3 (en)
FI (1) FI943660A (en)
HU (1) HUT68303A (en)
IL (1) IL104602A (en)
MA (1) MA22788A1 (en)
MX (1) MX9300676A (en)
NO (1) NO942925L (en)
NZ (1) NZ249382A (en)
OA (1) OA10090A (en)
RU (1) RU94045824A (en)
SI (1) SI9300065A (en)
TW (1) TW327175B (en)
WO (1) WO1993016097A1 (en)
ZA (1) ZA93801B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206413D0 (en) * 1992-03-24 1992-05-06 Smithkline Beecham Corp N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph a
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
IL104601A0 (en) * 1992-02-07 1993-07-08 Smithkline Beecham Corp Process for the preparation of steroidal dienes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9316097A1 *

Also Published As

Publication number Publication date
JPH07505140A (en) 1995-06-08
BG98955A (en) 1995-06-30
AU666177B2 (en) 1996-02-01
FI943660A0 (en) 1994-08-05
WO1993016097A1 (en) 1993-08-19
BR9305837A (en) 1997-02-18
MA22788A1 (en) 1993-10-01
NO942925D0 (en) 1994-08-05
HU9402303D0 (en) 1994-10-28
RU94045824A (en) 1996-07-10
MX9300676A (en) 1994-07-29
ZA93801B (en) 1993-11-05
KR950700319A (en) 1995-01-16
EP0643724A4 (en) 1995-05-10
NO942925L (en) 1994-08-08
NZ249382A (en) 1996-05-28
IL104602A0 (en) 1993-07-08
TW327175B (en) 1998-02-21
IL104602A (en) 1997-07-13
CZ188794A3 (en) 1994-12-15
SI9300065A (en) 1993-09-30
HUT68303A (en) 1995-06-28
CN1078475A (en) 1993-11-17
CA2129342A1 (en) 1993-08-19
AU3612693A (en) 1993-09-03
OA10090A (en) 1996-12-18
FI943660A (en) 1994-08-05
AP9600790A0 (en) 1996-04-30

Similar Documents

Publication Publication Date Title
US6717002B2 (en) Method of producing steroid derivatives
JPS61251650A (en) Manufacture of (z)-1-phenyl-1-diethylaminocarbonyl-2- aminomethylcyclopropanehydrochloride
UA43824C2 (en) ALPHA-IODO OR ALPHA-BROMOAMIDE AND METHOD OF OBTAINING THEM
CN111533677A (en) Method for synthesizing arbidol hydrochloride intermediate
EP0643724A1 (en) Process of preparing 3-carbonylandrostadiene 17-carboxamides
CN109053446B (en) Application of metal hydride/palladium compound system in preparation of 1, 3-dicarbonyl compound by series reaction of electron-deficient alkene compound
CN115181150A (en) Method for synthesizing ursodesoxycholic acid from phytosterol degradation product
CN109020864B (en) Application of metal hydride/palladium compound catalytic reduction system in reduction of alkenyl active methylene compound and reduction method
CN111138345A (en) Method for synthesizing polysubstituted pyridine derivative based on oxime ester and unsaturated ketone under catalysis of iron salt
US4486599A (en) Process for preparing the 2',4'-difluoro-4-hydroxy-(1,1'-diphenyl)-3-carboxylic acid
CZ401399A3 (en) Process of removing heavy metals
US5380926A (en) Method of making 3-methoxy-2,4,5-trifluorobenzoic acid
JP4032220B2 (en) Alicyclic tetracarboxylic acid compound and process for producing the same
PL118827B1 (en) Method of manufacture of tricyclicdiketone
CN113336780B (en) Preparation method of 2-formyl-4- (4-cyanophenoxy) phenylboronic acid pinacol ester
AU627609B2 (en) New quinoline derivatives and process for the preparation thereof
WO1991001315A1 (en) New quinoline derivatives and process for the preparation thereof
JP5000031B2 (en) Method for producing aromatic-o-dialdehyde compound
CN113214111A (en) Preparation method of 3- (2-cyanophenyl) propionic acid and 4-cyano-1-indanone
CN112588319A (en) Application of silane and synthesis of tauroursodeoxycholic acid under catalysis of silane
WO1993016098A1 (en) Process of preparing 3-acylandrostadienes
JPH0523255B2 (en)
KR930009817B1 (en) Process for preparation of pyridine derivatives
WO1996011206A1 (en) Process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids
JP2019069908A (en) Production method of dipyridyl ethylene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940802

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950327

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07J 41/00

17Q First examination report despatched

Effective date: 19970217

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19980521

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012402

Country of ref document: HK